Sanofi reports Q1 growth with Altuviiio sales doubling to €251M and Dupixent reaching €3.5B; company terminates two cancer ...

As Sanofi anticipates sales of immunotherapy juggernaut Dupixent reaching a major $22 billion by the end of the decade, ...

The FDA has cleared their once-weekly Factor VIII replacement therapy Altuviiio (efanesoctocog alfa) for adults and children with haemophilia A, giving Sanofi and Sobi a successor to well ...

In 2025, sales are anticipated to grow by a mid-to-high single-digit percentage at CER 5. Sanofi confirms the expectation of a strong rebound in business EPS with growth at a low double-digit ...

Other new drugs include Roche Holding AG’s Hemlibra and Sanofi’s Altuviiio, although both are only for hemophilia A patients. Both of those medicines need to be taken more regularly than ...

It believes that its three new products launched/added in 2023, Altuviiio (for hemophilia A), Beyfortus (for RSV) and Tzield (for type 1 diabetes), together can add up to at least €5 billion in ...

Business EPS was EUR 1.79, up 15.7% at CER and up 17.0% reported. Reports Q1 IRFS net sales EUR 9.9B, up 10.8% reported and up 9.7% at CER.

Sanofi confirms the expectation of a strong rebound in business EPS with growth at a low double-digit percentage at CER (before share buyback)6 • Sanofi intends to complete a share buyback program in ...

Sanofi: strong Q1 performance and 2025 guidance confirmed Paris, April 24, 2025 Q1 sales growth of 9.7% at CER1 and business EPS2 of €1.79 Pharma launches reached sales of €0.8 billion, up ...

Sanofi: strong Q1 performance and 2025 guidance confirmed Paris, April 24, 2025 Q1 sales growth of 9.7% at CER1 and business EPS2 of €1.79 Pharma launches reached sales of €0.8 billion, up 43.8%, driv ...